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Abstract
Aims: The aim of this study was to evaluate the low-density lipoprotein cholesterol lowering efficacy and safety of a
bempedoic acid 180 mg and ezetimibe 10 mg fixed-dose combination in patients with hypercholesterolemia and a high
risk of cardiovascular disease receiving maximally tolerated statin therapy.
Methods: This phase 3, double-blind clinical trial enrolled adult patients at high risk of cardiovascular disease
due to atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or multiple cardiovascu-
lar disease risk factors. Patients were randomly assigned (2:2:2:1) to treatment with the fixed-dose combin-
ation, bempedoic acid 180 mg, ezetimibe 10 mg or placebo added to stable background statin therapy for 12 weeks.
The primary efficacy endpoint was the percentage change from baseline to week 12 in low-density lipoprotein
cholesterol.
Results: Among the 301 patients included in the primary analysis, the mean baseline low-density lipoprotein cholesterol
level was 3.87 mmol/L (149.8 mg/dL). At week 12, the fixed-dose combination lowered low-density lipoprotein choles-
terol (–36.2%) significantly more than placebo (1.8% (placebo-corrected difference –38.0%); P< 0.001), ezetimibe alone
(–23.2%; P< 0.001) or bempedoic acid alone (–17.2%; P< 0.001). The fixed-dose combination lowered low-density
lipoprotein cholesterol levels similarly across subgroups, including patients receiving high-intensity, other-intensity or
no statin therapy. Improvements with the fixed-dose combination were also observed in secondary efficacy endpoints,
including high-sensitivity C-reactive protein. In this trial, fixed-dose combination treatment had a generally similar safety
profile compared with bempedoic acid, ezetimibe or placebo.
Conclusion: The bempedoic acid and ezetimibe fixed-dose combination significantly lowered low-density lipoprotein
cholesterol versus placebo or other oral monotherapies and had a favourable safety profile when added to maximally
tolerated statin therapy in patients with hypercholesterolemia and high cardiovascular disease risk.
Trial Registration: ClinicalTrials.gov identifier: NCT03337308.
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Introduction
For more than three decades, pharmacological lipid low-
ering has helped reduce cardiovascular disease (CVD)
risk in patients with hypercholesterolemia.1 Nonetheless,
despite the development of effective therapeutic options,
including statins, ezetimibe and proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors, many patients
fail to achieve adequate lowering of low-density lipopro-
tein (LDL) cholesterol.2–5 As a result, patients remain at
elevated CVD or cardiovascular event risk due to persist-
ent elevations in LDL-cholesterol, particularly patients
with atherosclerotic cardiovascular disease (ASCVD),
familial hypercholesterolemia or multiple CVD risk fac-
tors.6,7 The limitations of available therapies in terms of
effectiveness as well as tolerability, adherence and access
highlight the unmet need for additional therapeutic
options for lipid lowering.
Bempedoic acid is a once-daily, oral, first-in-class
adenosine triphosphate-citrate lyase (ACL) inhibitor.
ACL is a cytosolic enzyme integral to the cholesterol
synthesis pathway that acts upstream of hydroxy-
methylglutaryl coenzyme A (HMG-CoA) reductase.8
This mechanism of action is distinct from other lipid-
lowering therapies, including statins (which target
HMG-CoA reductase) and ezetimibe (an inhibitor of
intestinal cholesterol absorption). By inhibiting ACL,
bempedoic acid suppresses cholesterol synthesis,8
thereby triggering the upregulation of LDL receptor
expression in the liver, resulting in increased clearance
of LDL particles and lowering of LDL-cholesterol in
the blood.6 In pivotal clinical trials, bempedoic acid
as monotherapy or when added to background lipid-
lowering therapy significantly lowered LDL-cholesterol
as well as other relevant lipids and biomarkers.9–12
Therapeutic interventions whose lipid-lowering
effects are attributed to the upregulation of LDL recep-
tor expression (e.g. diet, statins, ezetimibe, bile acid
sequestrants and ileal bypass surgery) have been
shown to reduce adverse cardiovascular outcome risk
commensurate with the magnitude of LDL-cholesterol
reduction.1,13 As bempedoic acid and ezetimibe both
lower LDL-cholesterol by the upregulation of LDL
receptor expression, an effect achieved through disparate
mechanisms, there is a strong rationale for the develop-
ment of a fixed-dose combination (FDC) of the two
agents. This study evaluated the efficacy and safety of
a bempedoic acid 180mg and ezetimibe 10mg FDC
compared with placebo, ezetimibe 10mg alone, and
bempedoic acid 180mg alone in patients with hyperchol-
esterolemia at high CVD risk who were receiving max-
imally tolerated background statin therapy.
Methods
Patients
The study (ClinicalTrials.gov identifier: NCT03337308)
enrolled adults at high CVD risk due to the presence of
ASCVD, heterozygous familial hypercholesterolemia
(HeFH) or multiple CVD risk factors. Documented
ASCVD included a history of acute myocardial infarc-
tion (MI), silent MI, unstable angina, coronary revas-
cularisation procedures, clinically significant coronary
heart disease (CHD), symptomatic peripheral arterial
disease or cerebrovascular atherosclerotic disease.
The presence of multiple CVD risk factors was defined
as diabetes plus one other risk factor or three CVD risk
factors from the following list: age (men 45 years,
women 55 years); family history of CHD; smoking;
hypertension; low high-density lipoprotein (HDL)
cholesterol; or coronary calcium score above the 95th
percentile for the patient’s age, sex, and race/ethnicity.
Fasting LDL-cholesterol was required to be
2.6mmol/L or greater (100mg/dL; ASCVD and/or
HeFH) or 3.4mmol/L or greater (130mg/dL; multiple
CVD risk factors) while receiving stable maximally tol-
erated statin therapy. A patient’s maximally tolerated
statin therapy was determined by the investigator using
his or her medical judgement and local standards of
care, and may have included statin regimens other
than daily dosing or no statin therapy. Patients were
excluded from the study if they had total fasting trigly-
cerides of 5.6mmol/L or greater (500mg/dL), body
mass index (BMI) of 40 kg/m2 or greater, recent cardio-
vascular or cerebrovascular event or procedure (within
3 months prior to screening), or other clinically relevant
disease that would interfere with study participation.
Patients were prohibited from using systemic cortico-
steroids, simvastatin at doses of 40mg/day or greater,
fibrates, niacin and derivatives, bile acid sequestrants,
PCSK9 inhibitors, mipomersen, lomatipide, cholesteryl
ester transfer protein inhibitors, or red yeast rice-
containing products or undergoing apheresis during
the study or within specified intervals before screening.
All patients provided written informed consent.
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Study design
This phase 3, multicentre, double-blind study was
conducted at 78 sites in the United States from
23 October 2017 to 3 July 2018. Patients who met the
study inclusion criteria were randomly assigned 2:2:2:1
to oral, once-daily treatment with bempedoic acid
180mg and ezetimibe 10mg (BAþEZE FDC), bempe-
doic acid 180mg, ezetimibe 10mg or placebo for
12 weeks. Random assignment was stratified by CVD
risk category (ASCVD and/or HeFH vs. multiple CVD
risk factors) and baseline statin intensity (high intensity
vs. other). Atorvastatin 40–80mg/day and rosuvastatin
20–40mg/day were considered high-intensity statin
regimens; all other statin dosing regimens were cate-
gorised as ‘other intensity’ for the purposes of
random assignment. The protocol and informed con-
sent documents were reviewed and approved by the
institutional review board prior to initiation of the
study at each site.
Assessments
Clinical laboratory samples for the analysis of basic fast-
ing lipids (total cholesterol, calculated LDL-cholesterol,
HDL-cholesterol, non-HDL-cholesterol and triglycer-
ides) were collected at the screening visit and before
dosing on day 1 and weeks 4, 8 and 12. Samples for
quantification of apolipoprotein B and high-sensitivity
C-reactive protein (hsCRP) were collected before
dosing on day 1 and at week 12. LDL-cholesterol con-
centration was calculated using the Friedewald formula;
however, direct measurement was performed when tri-
glycerides were greater than 4.5mmol/L (400mg/dL) or
LDL-cholesterol was less than 1.3mmol/L (50mg/dL).
All lipid measurements were conducted at a central
laboratory (ICON, North Wales, Pennsylvania, USA).
Blood samples for analysis of trough plasma concentra-
tions of bempedoic acid, its active metabolite and ezeti-
mibe were collected before dosing at weeks 4, 8 and 12.
Safety assessments included continuous monitoring of
treatment-emergent adverse events (AEs) as well as clin-
ical laboratory values, vital sign measurements, weight
changes, physical examination findings and electrocar-
diogram readings. AEs of special interest were identified
based on preclinical and clinical findings for bempedoic
acid and other lipid-lowering therapies, and included
metabolic acidosis, hepatic safety, muscular safety,
new-onset diabetes/hyperglycemia, renal safety, cardio-
vascular events and neurocognitive/neurological events.
Statistical analysis
The planned sample size of 100 patients per active treat-
ment group and 50 patients in the placebo arm was
selected to provide adequate power for detecting
between-group differences in the primary efficacy meas-
ure. Assuming a treatment difference of 13% (standard
deviation (SD) 25%) for percentage change in LDL-
cholesterol at week 12 between the BAþEZE FDC
and ezetimibe or bempedoic acid, 100 patients in each
of these groups would provide 95% or greater power to
detect such a difference at an alpha level of 0.05 using a
two-sided t-test. Similarly, 100 patients in both the
BAþEZE FDC and bempedoic acid groups would
provide 98% or greater power to detect a slightly
larger treatment effect (15%; SD 25%). Finally, 100
patients in the BAþEZE FDC arm and 50 patients
in the placebo arm would provide over 99% power to
detect an estimated treatment effect of at least 33%
(SD 25%). Together, a total sample size of 350 patients
with a 2:2:2:1 allocation ratio to BAþEZE FDC, bem-
pedoic acid, ezetimibe and placebo would provide an
overall power of at least 92% (95% 98% 99%) to
detect the estimated treatment differences.
Prespecified efficacy analyses were performed using the
intention-to-treat (ITT) population, which included all
randomly assigned patients, and prespecified safety ana-
lyses included all patients who were randomly assigned
and received one or more dose of the study drug.
However, following database lock and review, it was
determined that an unusual number of patients (n¼ 51)
receiving active study drug (BAþEZE FDC, bempedoic
acid or ezetimibe but not placebo) who were reported to
have routinely ingested the study drug had no detectable
study drug in blood samples taken at week 12 for use in
population pharmacokinetic modelling. These patients
were evenly distributed among the three active treatment
arms. Subsequent investigation revealed that most (34 of
51) of these patients were from three study sites, which
were all located in the same metropolitan area and
together randomly assigned 67 patients to active treat-
ment and 14 to placebo. A root cause analysis ruled
out issues with the production or distribution of study
drug and the handling or analysis of pharmacokinetic
samples. Inferential evidence indicated an indeterminate
period of time when patients from these three sites were
not taking the study drug as directed by the study proto-
col, which raised concerns about the integrity of any of
the data from these three sites. Because of concerns that
data from these three sites would not accurately reflect
either the safety or efficacy of experimental therapy, data
from these three sites were excluded from the additional
post hoc efficacy and safety analyses reported here. Data
from the ITT and safety populations that included these
three sites are available in the Supplementary materials
(Supplementary Tables 1–3 and Supplementary Figure 1).
The primary endpoint was the percentage change
from baseline to week 12 in LDL-cholesterol. The three
comparisons between the BAþEZE FDC and the other
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treatment arms (BAþEZE FDC vs. placebo, BAþEZE
FDC vs. ezetimibe and BAþEZE FDC vs. bempedoic
acid) were co-primary endpoints. Comparisons were ana-
lysed using analysis of covariance, with treatment group
and random assignment stratification as factors and
baseline LDL-cholesterol as a covariate. Missing values
were imputed using a multiple imputation method,
taking into account adherence to treatment. Each of
the co-primary endpoint comparisons was conducted at
a significance level of 0.05. If all three tests within the co-
primary endpoint family achieved statistical significance,
the hypothesis testing continued to the secondary end-
points; otherwise, all statistical comparisons for second-
ary endpoints were to be considered descriptive only.
Least squares means, standard errors, 95% confidence
intervals (CIs) and associated P values were calculated
for each treatment group as well as for each treatment
group comparison.
Key secondary efficacy endpoints, which included
percentage change from baseline to week 12 in
hsCRP, non-HDL-cholesterol, total cholesterol and
apolipoprotein B, were analysed in a manner similar
to the primary efficacy endpoint. The alpha allocation
for secondary endpoints among the three comparison
groups was: alpha¼ 0.01 for BAþEZE FDC versus
placebo, alpha¼ 0.02 for BAþEZE FDC versus ezeti-
mibe and alpha¼ 0.02 for BAþEZE FDC versus bem-
pedoic acid. For hsCRP, a non-parametric analysis
(Wilcoxon rank sum test) with Hodges–Lehmann
estimates and CIs was performed. Changes in HDL-
cholesterol and triglycerides were summarised using
descriptive statistics.
Subgroup analyses for the change from baseline in
LDL-cholesterol were performed for the following
groups: sex, age (<65 vs. 65 years), baseline CVD
risk category, baseline statin intensity (high intensity,
other intensity, no statin), race (white vs. other), base-
line LDL-cholesterol category (<3.4mmol/L vs. 3.4
to< 4.1mmol/L vs. 4.1mmol/L), history of diabetes
and BMI (<25 kg/m2, 25 to< 30 kg/m2, 30 kg/m2).
The percentage change from baseline was analysed
using analysis of covariance, with treatment group,
subgroup, and treatment by subgroup interaction as
factors and baseline LDL-cholesterol as a covariate.
No imputation was performed for missing data in
subgroup analyses. Statistical analyses were performed
using SAS version 9.4 (SAS Institute Inc., Cary,
NC, USA).
Results
Of the 821 patients screened, 382 were randomly
assigned to treatment with BAþEZE FDC (n¼ 108),
bempedoic acid (n¼ 110), ezetimibe (n¼ 109) or placebo
(n¼ 55) (Figure 1). A total of 338 (88.5% of randomly
assigned) patients completed study treatment; the pro-
portion who discontinued treatment was similar among
the treatment groups. The exclusion of three study sites
in the same metropolitan area because of data integrity
concerns (see explanation in the Methods section)
affected 81 patients, who were distributed across the
treatment groups. The post hoc efficacy population
therefore comprised 301 patients. One patient who was
randomly assigned to BAþEZE FDC did not receive
any dose of study drug and was excluded from the
safety analyses. Data reported below are for the post
hoc population unless otherwise specified.
Adherence to study drug, as assessed by pill count,
was 80% or more for most patients in all treatment
groups (BAþEZE FDC, 92.9%; bempedoic acid,
90.9%; ezetimibe, 95.3%; placebo, 95.1%). Median
study drug exposure was 84 days in all active treatment
groups and 85 days in the placebo group.
The mean age of the study population was 64.3 (SD
9.5) years and 50.5% of patients were women (Table 1).
The majority (62.5%) of patients had ASCVD and/or
HeFH, and comorbid hypertension (>80%) and dia-
betes (>40%) were prevalent. Most patients had a base-
line mean LDL-cholesterol of 3.4mmol/L or greater
(130mg/dL) despite treatment with maximally tolerated
statin therapy, which consisted of a high-intensity statin
(34.6%), other-intensity statin (30.2%) or no statin
(35.2%).
Efficacy
At week 12, LDL-cholesterol lowering with BAþEZE
FDC was significantly greater than that for the placebo,
ezetimibe, or bempedoic acid groups (P< 0.001 for all
comparisons; Figure 2(a)), with BAþEZ FDC provid-
ing a reduction of 38.0% compared with placebo.
A significantly greater proportion of patients had
achieved LDL-cholesterol less than 2.6mmol/L
(100mg/dL) or less than 1.8mmol/L (70mg/dL) at
week 12 in the BAþEZE FDC treatment group
(67.5% and 31.3%, respectively) compared with the
placebo (17.5% and 0%; P< 0.001), ezetimibe (42.5%
and 10.0%; P 0.002) or bempedoic acid groups
(43.9% and 6.1%; P 0.003). At week 12, 33.7% of
patients in the BAþEZE FDC group had an LDL-
cholesterol reduction from baseline of 50% or greater
versus 0%, 5.0% and 3.7% of patients in the placebo,
ezetimibe and bempedoic acid groups, respectively
(P< 0.001 for all comparisons). LDL-cholesterol low-
ering with BAþEZE FDC was generally consistent in
subgroup analyses (Supplementary Figure 2). Although
the study was not powered to assess between-group dif-
ferences in the subgroup analyses, LDL-cholesterol
lowering with BAþEZE FDC was greater than
placebo in all subgroups (P 0.001). Moreover,
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BAþEZE FDC lowered LDL-cholesterol in all statin
intensity groups.
BAþEZE FDC reduced hsCRP by 35.1% com-
pared with an increase of 21.6% in the placebo group
(P< 0.001) and a reduction of 8.2% in the ezetimibe
group (P¼ 0.002; Figure 2(b)). The comparison of
BAþEZE FDC versus bempedoic acid was not statis-
tically significant, probably due to the considerable
hsCRP lowering observed in the bempedoic acid treat-
ment group (–31.9%). For the other key secondary end-
points, BAþEZE FDC reduced non-HDL-cholesterol,
total cholesterol and apolipoprotein B more than pla-
cebo (P< 0.001), ezetimibe (P 0.003) or bempedoic
acid (P< 0.001; Table 2). The magnitude of reduction
for the primary and key secondary endpoint com-
parisons was greater in the post hoc analysis compared
with the ITT analysis (Supplementary Figure 1 and
Supplementary Table 2). Changes from baseline in
HDL-cholesterol and triglycerides were modest
(<10%) in all treatment groups.
Safety
Treatment-emergent AEs were reported by 176 (58.7%)
patients overall, and were more frequent in the
BAþEZE FDC and bempedoic acid groups than in
the ezetimibe or placebo groups (Table 3). Rates of
individual AEs were low (affecting< 7% of patients
per treatment group), and were generally mild or mod-
erate in intensity. No treatment-related serious AEs or
fatal AEs occurred during the study. The most common
treatment-related AEs in the BAþEZE FDC group
were blood uric acid increase, constipation, fatigue,
muscle spasms and oral discomfort, each reported by
two (2.4%) patients. Rates of AEs leading to treatment
discontinuation were similar in the active treatment
groups (BAþEZE FDC, 8.2%; bempedoic acid,
10.2%; ezetimibe, 11.6%). Myalgia led to treatment
discontinuation for three (3.4%) patients in the bempe-
doic acid group, one (1.2%) patient in the ezetimibe
group and no patients in the BAþEZE FDC group.
Other events that led to discontinuation in more than
Screened
(N = 821)
Randomized
(N = 382)
Screening failure (n = 439)
Bempedoic acid 180 mg
and ezetimibe 10 mg FDC
(n = 108)
Exclusion of 3 sites due to
data integrity concerns
(n = 22) 
Premature discontinuation 
of treatment (n = 10; 11.6%)
Discontinued study
(n = 5; 5.8%) 
Analysis populations Analysis populations Analysis populations Analysis populations
Discontinued study
(n = 6; 6.8%) Discontinued study
(n = 5; 5.8%) Discontinued study(n = 1; 2.4%) 
Premature discontinuation 
of treatment (n = 13; 14.8%) Premature discontinuation 
of treatment (n = 13; 15.1%)
Premature discontinuation 
of treatment (n = 5; 12.2%)
Adverse event (n = 7)
Adverse event (n = 2)
Post hoc efficacy (n = 86)
Intention to treat (n = 108) Intention to treat (n = 110) Intention to treat n = 109) Intention to treat (n = 55)
Safety (n = 55)Safety (n = 109)Safety (n = 110)Safety (n = 107)a
Post hoc efficacy (n = 88) Post hoc efficacy (n = 86) Post hoc efficacy (n = 41)
Post hoc safety (n = 41)Post hoc safety (n = 86)Post hoc safety (n = 88)Post hoc safety (n = 85)a
Adverse event (n = 3)
Adverse event (n = 2)
Adverse event (n = 10)
Patient withdrew (n = 3)
Patient withdrew (n = 2) Patient withdrew (n = 1) Adverse event (n = 3) Adverse event (n = 1)Patient withdrew (n = 2)
Patient withdrew (n = 1)
Patient withdrew (n = 3) Protocol violation (n = 1)
Adverse event (n = 9)
Patient withdrew (n = 2)
Protocol violation (n = 1)
Protocol violation (n = 1)
Other (n = 1)
Lost to follow-up (n = 1)
Lost to follow-up (n = 1) Lost to follow-up (n = 1)
Exclusion of 3 sites due to
data integrity concerns
(n = 22) 
Exclusion of 3 sites due to
data integrity concerns
(n = 23) 
Exclusion of 3 sites due to
data integrity concerns
(n = 14) 
Bempedoic acid 180 mg
(n = 110)
Ezetimibe 10 mg
(n = 109)
Placebo
(n = 55) 
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Figure 1. Patient disposition. aOne patient randomly assigned to the bempedoic acid and ezetimibe fixed-dose combination (FDC)
treatment group did not receive any dose of study drug and was therefore excluded from the safety analyses.
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one patient were oral discomfort (BAþEZE FDC, two
patients (2.4%)) and fatigue (BAþEZE FDC, one
patient (1.2%); bempedoic acid, one patient (1.1%)).
Analysis of AEs of special interest did not reveal any
new safety signals with BAþEZE FDC versus bempe-
doic acid or ezetimibe. The incidence of AEs in the mus-
cular disorders category was similar among treatment
groups (Table 3). No patient had a repeated and con-
firmed creatine kinase elevation more than 5 the upper
limit of normal (ULN), and one patient in the BAþEZE
FDC group had a repeated and confirmed aspartate ami-
notransferase elevation greater than 3ULN (aspartate
aminotransferase levels were also> 3ULN at random
assignment for this patient). A modest increase in mean
uric acid levels was observed in the BAþEZE FDC
(11.8%) and bempedoic acid (16.1%) treatment groups,
but no patient in any treatment group reported an AE of
gout. Safety findings in the post hoc population were
consistent with those observed in the overall safety popu-
lation (Supplementary Table 3).
Table 1. Baseline patient demographics and characteristics, post hoc population.
Characteristic
BAþ EZE FDC
(n¼ 86)
Bempedoic acid
180 mg (n¼ 88)
Ezetimibe
10 mg (n¼ 86)
Placebo
(n¼ 41)
Age, years 62.2 9.5 65.0 9.8 65.1 8.4 65.4 10.8
Women, n (%) 44 (51.2) 48 (54.5) 43 (50.0) 17 (41.5)
Race, n (%)
White 67 (77.9) 70 (79.5) 72 (83.7) 34 (82.9)
Black or African American 16 (18.6) 17 (19.3) 12 (14.0) 7 (17.1)
Ethnicity, n (%)
Hispanic or Latino 10 (11.6) 11 (12.5) 9 (10.5) 6 (14.6)
Not Hispanic or Latino 76 (88.4) 77 (87.5) 77 (89.5) 35 (85.4)
CV risk category, n (%)
ASCVD and/or HeFH 53 (61.6) 55 (62.5) 54 (62.8) 26 (63.4)
Multiple CV risk factors 33 (38.4) 33 (37.5) 32 (37.2) 15 (36.6)
History of diabetes, n (%) 35 (40.7) 45 (51.1) 43 (50.0) 17 (41.5)
History of hypertension, n (%) 74 (86.0) 77 (87.5) 71 (82.6) 35 (85.4)
Body mass index, kg/m2 31.1 6.3 30.6 5.5 29.9 4.4 30.7 4.2
eGFR category, n (%)
90 mL/min/1.73 m2 30 (34.9) 27 (30.7) 29 (33.7) 19 (46.3)
60 to< 90 mL/min/1.73 m2 40 (46.5) 41 (46.6) 43 (50.0) 14 (34.1)
<60 mL/min/1.73 m2 16 (18.6) 20 (22.7) 14 (16.3) 8 (19.5)
Baseline statin intensity, n (%)
High intensity 31 (36.0) 29 (33.0) 28 (32.6) 16 (39.0)
Other intensity 22 (25.6) 32 (36.4) 26 (30.2) 11 (26.8)
No statin 33 (38.4) 27 (30.7) 32 (37.2) 14 (34.1)
Total cholesterol, mmol/La 6.14 1.26 5.83 1.12 5.98 1.31 5.98 1.30
Non-HDL-C, mmol/La 4.87 1.21 4.54 1.05 4.66 1.22 4.68 1.29
LDL-C, mmol/La 3.98 1.05 3.75 0.99 3.85 1.08 3.95 1.21
LDL-C category, n (%)
<3.4 mmol/L 30 (34.9) 40 (45.5) 31 (36.0) 13 (31.7)
3.4 to< 4.1 mmol/L 24 (27.9) 23 (26.1) 30 (34.9) 10 (24.4)
4.1 mmol/L 32 (37.2) 25 (28.4) 25 (29.1) 18 (43.9)
HDL-C, mmol/La 1.27 0.38 1.29 0.32 1.33 0.41 1.30 0.36
Triglycerides, mmol/Lb 1.77 (1.20, 2.36) 1.59 (1.22, 2.15) 1.62 (1.24, 2.40) 1.57 (1.18, 1.90)
Apolipoprotein B, mg/dLa 121.1 30.9 113.4 26.4 115.5 31.3 115.1 32.5
hsCRP, mg/Lb 3.1 (1.7, 6.2) 2.9 (1.4, 5.0) 2.8 (1.3, 5.9) 3.0 (1.3, 5.5)
ASCVD: atherosclerotic cardiovascular disease; BAþ EZE FDC: bempedoic acid and ezetimibe fixed-dose combination; CV: cardiovascular; eGFR:
estimated glomerular filtration rate; HDL-C: high-density lipoprotein cholesterol; HeFH: heterozygous familial hypercholesterolemia; hsCRP: high-
sensitivity C-reactive protein; LDL-C: low-density lipoprotein cholesterol.
aData are means standard deviations.
bData are medians (interquartile ranges).
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Discussion
In this study of patients with high CVD risk and hyper-
cholesterolemia despite treatment with maximally tol-
erated statin therapy, treatment with BAþEZE FDC
resulted in statistically significant LDL-cholesterol
lowering compared with placebo, ezetimibe and bempe-
doic acid. The extent of lipid lowering in the BAþEZE
FDC treatment group suggests an additive effect of
bempedoic acid and ezetimibe, wherein lipid reductions
with the combination were greater than those seen
with the individual components alone. Additive effects
are consistent with the known differences in mechan-
isms of action of bempedoic acid8 and ezetimibe14 and
with previous clinical data.9,15 In a phase 2 study,
combination therapy with bempedoic acid 180mg and
ezetimibe 10mg in patients not receiving other lipid-
modifying therapies lowered LDL-cholesterol by
48%. In the monotherapy arms, LDL-cholesterol low-
ering was 30% with bempedoic acid 180mg and 21%
with ezetimibe 10mg.15 The addition of bempedoic acid
180mg to stable ezetimibe therapy with or without
other lipid-modifying therapies (including statins) in
a phase 3 study yielded an additional 24% LDL-
cholesterol lowering.9 Together, these results indicate
a complementary effect on LDL-cholesterol lowering
when combining bempedoic acid and ezetimibe.
BAþEZE FDC lowered LDL-cholesterol to a degree
generally consistent across demographic and clinical
subgroups, including patients receiving various intensi-
ties of background statin therapy. The use of a high-
intensity statin regimen was reported by more than
one-third of patients enrolled in the study. Within this
subgroup, treatment with BAþEZE FDC lowered
LDL-cholesterol by 38.9% (beyond any statin-mediated
LDL-cholesterol lowering). The study population also
included a large segment (31–38%) of patients who
were not receiving a statin due to statin intolerance.
Within this subgroup, treatment with BAþEZE FDC
lowered LDL-cholesterol by 38.8%. These findings
support the potential for substantial LDL-cholesterol
lowering with BAþEZE FDC in diverse patient popu-
lations, independent of baseline statin use.
BAþEZE FDC also reduced circulating concentra-
tions of key secondary endpoints, including hsCRP,
non-HDL-cholesterol, total cholesterol and apolipo-
protein B. Reductions in hsCRP with BAþEZE
FDC and bempedoic acid were –35.1% and –31.9%,
respectively. These reductions were achieved on top of
stable background statin therapy, which is also known
to reduce hsCRP levels.16 The comparatively lower
reduction in hsCRP with ezetimibe observed in the cur-
rent study (–8.2%) is consistent with previous reports
of a 9% to 10% reduction in hsCRP when ezetimibe is
added to a statin.17,18 Hence, the overall reduction in
hsCRP with BAþEZE FDC appeared to be largely
driven by the effects of bempedoic acid. Additive effects
of BAþEZE FDC were observed in lowering of non-
HDL-cholesterol, total cholesterol and apolipoprotein B.
Apolipoprotein B lowering was concordant with that
of LDL-cholesterol, although reduction of the former
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Figure 2. Change from baseline to week 12 in low-density
lipoprotein (LDL) cholesterol and high-sensitivity C-reactive
protein (hsCRP), post hoc population. (a) Percentage change
from baseline in LDL-cholesterol was analysed using analysis of
covariance with treatment group and random assignment strati-
fication as factors and baseline LDL-cholesterol as a covariate.
Baseline was defined as the mean of the values from week –2 and
pre-dose on day 1. Missing values were imputed using a multiple
imputation method, taking into account adherence to treatment.
Bars represent least-squares means standard errors. (b)
Percentage change from baseline in hsCRP was analysed using a
non-parametric (Wilcoxon rank sum test) analysis with Hodges–
Lehmann estimates and confidence intervals. Baseline was
defined as the value recorded pre-dose on day 1. Bars represent
medians. Data are as observed, without imputation for missing
values. Between-group differences are shown with 95% confi-
dence intervals for LDL-cholesterol and (1 – alpha) percentage
confidence intervals for hsCRP. The BAþ EZE FDC versus pla-
cebo comparison used alpha¼ 0.01, and the BAþ EZE FDC
versus ezetimibe and BAþ EZE FDC versus bempedoic acid
comparisons used alpha¼ 0.02. BAþ EZE FDC: bempedoic acid
and ezetimibe fixed-dose combination; NS: not significant.
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was slightly less than that of LDL-cholesterol in a
manner that has been described with statins and ezeti-
mibe.19–21 These improvements coupled with substan-
tial LDL-cholesterol lowering support a positive role
for BAþEZE FDC in ameliorating hyperlipidemia
and reducing inflammation.
BAþEZE FDC had a favourable safety profile and
was well tolerated when added to background max-
imally tolerated statin therapy. Safety and tolerability
findings were consistent with expectations based on
previous bempedoic acid clinical trials,9–12 and no
new safety concerns were detected with BAþEZE
FDC treatment compared with bempedoic acid, ezeti-
mibe or placebo. The incidences of AEs and serious
AEs were similar in the BAþEZE FDC group com-
pared with the other active treatment groups, as were
the rates of discontinuations due to AEs. No differences
in the safety profile of BAþEZE FDC were observed
in demographic or clinical subgroups, including
patients who were receiving background high-intensity
statin therapy.
From a clinical standpoint, BAþEZE FDC has sev-
eral potential advantages. LDL-cholesterol goal
achievement in clinical practice remains an elusive
aspiration, particularly among those at high or very
high cardiovascular risk.22,23 Statin therapy alone may
be insufficient to achieve LDL-cholesterol goals,6 and a
single, oral, once-daily, add-on therapy with demon-
strated lipid-lowering efficacy and statin compatibility
is an attractive option. BAþEZE FDC may also be a
viable alternative for patients with statin intolerance,
for whom dyslipidemia management guidelines cur-
rently recommend ezetimibe and/or bile acid seques-
trants.6 Bempedoic acid acts through the same
pathway as statins, yet due to its selective activation
in the liver but not skeletal muscle,24 bempedoic acid
is not associated with muscle-related side effects, even
among patients with a history of statin intolerance.9,11
Finally, although there are not cardiovascular out-
comes data for bempedoic acid at this time, its mech-
anism (LDL-cholesterol lowering through upregulation
of LDL receptor expression)1,13 and Mendelian ran-
domisation analysis of genetic variants whose effects
are akin to endogenous inhibition of ACL25 – the
target of bempedoic acid – support its potential for
reducing cardiovascular outcome risks.
The limitations of this study include its relatively
short duration (12 weeks) and the occurrence of slight
Table 2. Percentage changes in key secondary endpoints from baseline to week 12, post hoc population.
Parameter treatment n LS mean SE
Difference
(confidence interval)a P value
Non-HDL-C
BAþ EZE FDC vs. 86 –31.9 2.2
Placebo 41 1.8 3.3 –33.7 (–43.9, –23.4) <0.001c
Ezetimibe 86 –19.9 2.1 –12.1 (–19.1, –5.0) <0.001d
Bempedoic acid 88 –14.1 2.2 –17.8 (–25.1, –10.5) <0.001d
Total cholesterol
BAþ EZE FDC vs. 86 –26.4 1.9
Placebo 41 0.7 2.5 –27.1 (–35.1, –19.1) <0.001c
Ezetimibe 86 –16.0 1.6 –10.4 (–16.1, –4.6) <0.001d
Bempedoic acid 88 –12.1 1.8 –14.2 (–20.4, –8.1) <0.001d
Apolipoprotein Bb
BAþ EZE FDC vs. 82 –24.6 2.4
Placebo 38 5.5 3.0 –30.1 (–39.9, –20.3) <0.001c
Ezetimibe 84 –15.3 2.0 –9.3 (–16.5, –2.1) 0.003d
Bempedoic acid 85 –11.8 2.2 –12.8 (–20.3, –5.3) <0.001d
BA þ EZE FDC: bempedoic acid and ezetimibe fixed-dose combination; LDL-C: low-density lipoprotein cholesterol; LS: least-
squares; non-HDL-C: non-high-density lipoprotein cholesterol; SE: standard error.
The percentage change from baseline was analysed using analysis of covariance with treatment group and random assignment
stratification as factors and baseline value as a covariate. Missing values were imputed using a multiple imputation method, taking
into account adherence to treatment. Baseline for non-HDL-cholesterol and total cholesterol was defined as the mean of the
values from week –2 and pre-dose on day 1.
aConfidence intervals are (1 – alpha) percentage.
bBaseline for apolipoprotein B was defined as the value recorded pre-dose on day 1. Baseline data for apolipoprotein B were
available for 82, 38, 84 and 85 patients in the FDC, placebo, ezetimibe and bempedoic acid groups, respectively.
cBAþ EZE FDC versus placebo comparison used alpha¼ 0.01.
dBAþ EZE FDC versus ezetimibe and BAþ EZE FDC versus bempedoic acid comparisons used alpha¼ 0.02.
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imbalances in baseline demographics and patient char-
acteristics among treatment groups. In addition, as
noted in the Methods section, 81 patients from three
study sites were excluded due to data integrity concerns
(see explanation in the Methods section). Finally, this
study was not designed to evaluate CVD outcomes;
rather, the intent was limited to assessment of 12-week
lipid-altering efficacy and safety of BAþEZE FDC
relative to monotherapy with the component agents or
placebo. The influence of bempedoic acid on CVD event
risk is being evaluated in an ongoing CVD outcomes
trial (CLEAR Outcomes; ClinicalTrials.gov identifier:
NCT02993406). Although CLEAR Outcomes is not a
BAþEZE FDC study, because it is enrolling high-risk
patients with statin intolerance, the concomitant use of
bempedoic acid with ezetimibe is likely.
Table 3. Safety summary, post hoc population.
BAþ EZE FDC
(n¼ 85)
Bempedoic
acid (n¼ 88)
Ezetimibe
(n¼ 86)
Placebo
(n¼ 41)
Overview of AEs, number of patients (%)
Any treatment-emergent AE 53 (62.4) 58 (65.9) 47 (54.7) 18 (43.9)
Serious AEs 8 (9.4) 7 (8.0) 9 (10.5) 1 (2.4)
Study drug-related AEs 13 (15.3) 12 (13.6) 9 (10.5) 4 (9.8)
AEs leading to treatment discontinuation 7 (8.2) 9 (10.2) 10 (11.6) 2 (4.9)
Fatal AEs 0 0 0 0
Common AEs, number of patients (%)
Urinary tract infection 5 (5.9) 3 (3.4) 2 (2.3) 1 (2.4)
Nasopharyngitis 4 (4.7) 6 (6.8) 4 (4.7) 0
Constipation 4 (4.7) 0 2 (2.3) 0
Back pain 3 (3.5) 3 (3.4) 2 (2.3) 2 (4.9)
Fatigue 3 (3.5) 2 (2.3) 1 (1.2) 0
Upper respiratory tract infection 3 (3.5) 1 (1.1) 0 0
Blood creatinine increased 3 (3.5) 1 (1.1) 0 0
Blood uric acid increased 3 (3.5) 1 (1.1) 0 0
Bronchitis 3 (3.5) 0 3 (3.5) 0
Headache 2 (2.4) 3 (3.4) 1 (1.2) 1 (2.4)
Arthralgia 1 (1.2) 4 (4.5) 3 (3.5) 1 (2.4)
Hypertension 1 (1.2) 3 (3.4) 2 (2.3) 0
Acute myocardial infarction 1 (1.2) 2 (2.3) 3 (3.5) 0
Dyspnoea 0 0 1 (1.2) 2 (4.9)
Muscular disorders, number of patients (%) 6 (7.1) 7 (8.0) 7 (8.1) 3 (7.3)
Muscle spasms 2 (2.4) 1 (1.1) 4 (4.7) 0
Muscular weakness 0 0 0 1 (2.4)
Myalgia 2 (2.4) 5 (5.7) 2 (2.3) 1 (2.4)
Pain in extremity 2 (2.4) 2 (2.3) 1 (1.2) 1 (2.4)
Laboratory results
ALT or AST> 3ULN, n (%)c 1 (1.2) 0 0 0
Creatine kinase> 5ULN, n (%)c 0 0 0 0
Change in creatinine, mmol/Ld 2.0 10.2 5.6 11.7 2.7 17.4 –0.9 8.3
Change in uric acid, mmol/Ld 36.9 67.2 51.7 65.6 3.0 46.0 –8.9 47.6
AE: adverse event; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BAþ EZE FDC: bempedoic acid and ezetimibe fixed-dose com-
bination; ULN: upper limit of normal.
aTreatment-emergent AEs occurring in 3% or more of patients in any treatment group, excluding muscle-related AEs.
bMuscular disorders were predefined as: muscular weakness, muscle necrosis, muscle spasms, myalgia, myoglobin blood increased, myoglobin blood
present, myoglobin urine present, myoglobinemia, myoglobinuria, myopathy, myopathy toxic, necrotising myositis, pain in extremity and
rhabdomyolysis.
cPatients with repeated and confirmed aminotransferase or creatine kinase elevations.
dData are means standard deviations for change from baseline to week 12.
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Conclusions
The addition of BAþEZE FDC to maximally tolerated
statin therapy provides significant atherogenic lipid low-
ering compared with either agent alone or placebo.
BAþEZE FDC lowered LDL-cholesterol in patients
who were receiving high-intensity statin therapy as well
as patients who were statin intolerant. Clinical guidelines
and practice are moving towards the achievement of
lower LDL-cholesterol levels and more stringent treat-
ment targets. BAþEZE FDC may help provide a
potent and convenient therapy complementary to exist-
ing lipid-modifying therapy regimens.
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